Moderna, Inc. Share Price and Company Fundamentals



Price
$152.68
Change
-6.310 (-3.969%)
52 week
30.98 - 189.26

Last traded: Last Wednesday at 8:00 PM

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Key Metrics

PE ratio

-

PB ratio

23.77

Dividend yield

Beta

1.38

Market cap

$61.15B

Enterprise value

$65.03B

Company profile

Industry / SectorBiotechnology / Healthcare
Full time employees1300
Websitehttp://www.modernatx.com
Mailing address200 Technology Square Cambridge MA 02139 United States
Phone / Fax617 714 6500 / 617 583 1998

Dividends

Moderna, Inc. does not pay dividends.

Company Executives

As of May 2021, following are the company executives and directors listed on Moderna, Inc..

NameTitleAgeTotal Pay
Dr. Noubar B. Afeyan Ph.D.Co-Founder, Independent Non Exec. Chairman & Member of Technology Advisory Board57107.5k
Mr. Stephane BancelCEO & Director473.86M
Dr. Stephen HogePres441.26M
Mr. David W. MelineCFO & Principal Accounting Officer63932.62k
Dr. Tal ZaksChief Medical Officer541.25M
Mr. Juan AndresChief Technical Operations & Quality Officer551.25M
Dr. John V. W. ReyndersChief Information Officer
Dr. Melissa J. MooreChief Scientific Officer & Member of Scientific Advisory Board
Ms. Lavina Talukdar CFASr. VP & Head of Investor Relations
Ms. Lori M. Henderson J.D., Esq.Gen. Counsel & Corp. Sec.58

Profitability and management effectiveness

Profit margin

-92.99%

Operating margin

-94.99%

Return on assets

-10.69%

Return on equity

-39.99%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Moderna, Inc. is 61.15B and its enterprise value is 65.03B. The enterprise value to revenue ratio of MRNA is 80.94.

The MRNA's stocks Beta value is 1.38 making it 38% more volatile compared to NASDAQ market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Moderna, Inc. (NASDAQ:MRNA) Frequently Asked Questions

1. What is Moderna, Inc.'s Stock Symbol?

Moderna, Inc. trades on NASDAQ under the ticker symbol "MRNA".

2. What is Moderna, Inc.'s stock price today?

One share of MRNA stock can currently be purchased for approximately $152.68.

3. How can I contact Moderna, Inc.?

Moderna, Inc.'s mailing address is 200 Technology Square Cambridge MA 02139 United States. The company can be reached via phone at 617 714 6500.

4. What is Moderna, Inc.'s official website?

The official website of Moderna, Inc. is http://www.modernatx.com.